Literature DB >> 25497132

Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.

Luca Piemontese1, Giuseppe Fracchiolla1, Antonio Carrieri1, Mariagiovanna Parente1, Antonio Laghezza1, Giuseppe Carbonara1, Sabina Sblano1, Marilena Tauro1, Federica Gilardi2, Paolo Tortorella1, Antonio Lavecchia3, Maurizio Crestani4, Béatrice Desvergne2, Fulvio Loiodice5.   

Abstract

The effects resulting from the introduction of an oxime group in place of the distal aromatic ring of the diphenyl moiety of LT175, previously reported as a PPARα/γ dual agonist, have been investigated. This modification allowed the identification of new bioisosteric ligands with fairly good activity on PPARα and fine-tuned moderate activity on PPARγ. For the most interesting compound (S)-3, docking studies in PPARα and PPARγ provided a molecular explanation for its different behavior as full and partial agonist of the two receptor isotypes, respectively. A further investigation of this compound was carried out performing gene expression studies on HepaRG cells. The results obtained allowed to hypothesize a possible mechanism through which this ligand could be useful in the treatment of metabolic disorders. The higher induction of the expression of some genes, compared to selective agonists, seems to confirm the importance of a dual PPARα/γ activity which probably involves a synergistic effect on both receptor subtypes.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bioisosterism; Docking; Gene expression study; PPAR

Mesh:

Substances:

Year:  2014        PMID: 25497132     DOI: 10.1016/j.ejmech.2014.11.044

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

1.  Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.

Authors:  Letizia Giampietro; Antonio Laghezza; Carmen Cerchia; Rosalba Florio; Lucia Recinella; Fabio Capone; Alessandra Ammazzalorso; Isabella Bruno; Barbara De Filippis; Marialuigia Fantacuzzi; Claudio Ferrante; Cristina Maccallini; Paolo Tortorella; Fabio Verginelli; Luigi Brunetti; Alessandro Cama; Rosa Amoroso; Fulvio Loiodice; Antonio Lavecchia
Journal:  ACS Med Chem Lett       Date:  2019-02-25       Impact factor: 4.345

2.  Ampelopsin Improves Insulin Resistance by Activating PPARγ and Subsequently Up-Regulating FGF21-AMPK Signaling Pathway.

Authors:  Yong Zhou; Ying Wu; Yu Qin; Lei Liu; Jing Wan; Lingyun Zou; Qianyong Zhang; Jundong Zhu; Mantian Mi
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

3.  Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.

Authors:  Yan Chen; Hongmei Chen; Yochai Birnbaum; Manjyot K Nanhwan; Mandeep Bajaj; Yumei Ye; Jinqiao Qian
Journal:  Diab Vasc Dis Res       Date:  2017-01-23       Impact factor: 3.291

4.  New approaches for prevention and treatment of Alzheimer's disease: a fascinating challenge.

Authors:  Luca Piemontese
Journal:  Neural Regen Res       Date:  2017-03       Impact factor: 5.135

5.  Natural Scaffolds with Multi-Target Activity for the Potential Treatment of Alzheimer's Disease.

Authors:  Luca Piemontese; Gabriele Vitucci; Marco Catto; Antonio Laghezza; Filippo Maria Perna; Mariagrazia Rullo; Fulvio Loiodice; Vito Capriati; Michele Solfrizzo
Journal:  Molecules       Date:  2018-08-29       Impact factor: 4.411

6.  Synthesis of Novel 2,3-Dihydro-1,5-Benzothiazepines as α-Glucosidase Inhibitors: In Vitro, In Vivo, Kinetic, SAR, Molecular Docking, and QSAR Studies.

Authors:  Rabia Mehmood; Ehsan Ullah Mughal; Eslam B Elkaeed; Rami J Obaid; Yasir Nazir; Hanan A Al-Ghulikah; Nafeesa Naeem; Munirah M Al-Rooqi; Saleh A Ahmed; Syed Wadood Ali Shah; Amina Sadiq
Journal:  ACS Omega       Date:  2022-08-17

Review 7.  Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy.

Authors:  Asha Hiremathad; Luca Piemontese
Journal:  Neural Regen Res       Date:  2017-08       Impact factor: 5.135

8.  Beyond the Canonical Endocannabinoid System. A Screening of PPAR Ligands as FAAH Inhibitors.

Authors:  Leonardo Brunetti; Antonio Carrieri; Luca Piemontese; Paolo Tortorella; Fulvio Loiodice; Antonio Laghezza
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.